Prostate Cancer

Paper Summary:

Prostatic cancer is the most prevalent cancer in men and the second leading cause of cancer death. Despite intensified efforts to improve the diagnosis and treatment of PC, the death rate has remained unchanged for decades. This paper shows that while it is hoped that new screening approaches, including PSA testing, and increased use of radical prostatectomy will drop the death rate, the impact of these approaches on survival will not be known for another 10-15 years.

From the Paper:

"Because of the long period over which prostate cancer appears to develop, the chemoprevention or chemosuppression of prostate cancer growth appears to be a real possibility. Finasteride, an agent which inhibits the conversion of testosterone to its prostatic active metabolite dihydrotestosterone, is now in active clinical trials (17). Finasteride, in theory, will interfere with the promotional effects of hormones on prostate cells. Other agents, such as the retinoids, are under development as differentiation and anti-progresslon agents for bladder and prostate cancer."

More papers on Prostate Cancer:

• Analytical Essay # 123885 : "Capsaisin and Prostate Cancer"
• Term Paper # 125786 : "Prostate Cancer Prevention"
• Article Review # 122241 : "Article Review - Pomegranate Juice and Prostate Cancer"
• Essay # 74296 : "Biochemistry and Prostate Cancer"

APA Citation:

MLA Citation: